Investors may believe the company's poor revenue performance...
Investors may believe the company's poor revenue performance won't improve, causing a low P/S ratio. The company's future revenue growth is expected to be weaker than the industry average, causing discomfort among shareholders.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Held Back By Insufficient Growth Even After Shares Climb 60%
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment